Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 13 sources cited
Key Takeaways
- Zepbound is the brand name for tirzepatide, a once-weekly injectable approved by the FDA in November 2023 for chronic weight management.
- It's a dual GIP and GLP-1 receptor agonist, the first medication of its class approved for obesity. Mounjaro is the same drug, but approved for type 2 diabetes.
- In the SURMOUNT-1 trial, average weight loss at 72 weeks was 15.0%, 19.5%, and 20.9% on the 5 mg, 10 mg, and 15 mg doses respectively (Jastreboff et al., NEJM 2022).
- Zepbound was approved in March 2025 for obstructive sleep apnea in adults with obesity, the first weight-loss medication with that indication (FDA, 2025).
- Cash price runs about $1,059 per month at retail. Eli Lilly's self-pay vials (LillyDirect) start around $349-499 depending on dose.
Direct answer (40-60 words)
Zepbound is Eli Lilly's brand name for tirzepatide, a once-weekly injectable medication FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. It works by activating both GIP and GLP-1 receptors. Average weight loss is 15-22%.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The 30-second answer
- What Zepbound is, in plain English
- How Zepbound works (mechanism)
- Who it's approved for
- The dose schedule
- How much weight people lose on Zepbound
- Side effects you should know about
- Who shouldn't take Zepbound
- Zepbound vs Wegovy, Ozempic, Mounjaro
- Cost in 2026
- The compounded tirzepatide question
- FAQ
- Sources
- Footer disclaimers
- Article and FAQ schema
The 30-second answer
Zepbound is a prescription weight-loss medication. You take it as a once-weekly injection under the skin, similar to insulin technique. The active ingredient is tirzepatide, the same molecule sold as Mounjaro for diabetes. In trials, patients lost about 15-22% of their starting weight over 18 months on Zepbound combined with diet and exercise (Jastreboff et al., NEJM 2022).
It's not magic. It works by changing the brain and gut signals that control appetite and food intake. Most patients eat less because they don't feel hungry, not because they're forcing themselves.
What Zepbound is, in plain English
Zepbound (pronounced ZEP-bound) is the brand name for tirzepatide, made by Eli Lilly and Company. It's an injectable medication delivered through a single-use auto-injector pen, taken once per week.
The FDA approved Zepbound on November 8, 2023 for chronic weight management. Two years earlier (May 2022), the same molecule was approved under the brand name Mounjaro for adults with type 2 diabetes.
So if you've heard of Mounjaro, Zepbound is the same drug, same dose strengths, same mechanism. The only meaningful difference is what insurance and the FDA label say it's for.
In March 2025, the FDA expanded Zepbound's label to include obstructive sleep apnea (OSA) in adults with obesity. That made Zepbound the first weight-loss medication with a sleep-apnea indication, based on the SURMOUNT-OSA trial results (Malhotra et al., NEJM 2024).
How Zepbound works (mechanism)
Zepbound is a dual incretin receptor agonist. It activates two different receptors in the body:
- GLP-1 (glucagon-like peptide 1) receptors. Same target as semaglutide (Wegovy, Ozempic). Slows gastric emptying, increases satiety signals to the brain, and reduces food reward.
- GIP (glucose-dependent insulinotropic polypeptide) receptors. Additional incretin pathway not targeted by semaglutide. Appears to enhance the GLP-1 effect on appetite and may improve fat metabolism.
Both pathways are part of the body's natural incretin system, the hormones the gut releases after eating. Zepbound essentially turns up the volume on those signals continuously.
The practical result for most patients:
- You feel full faster during meals
- You stay full longer between meals
- Food noise (the constant background thinking about food) gets quieter
- Cravings for high-calorie foods diminish
- You spontaneously eat less without consciously dieting
Zepbound doesn't burn fat directly. It changes the inputs to your eating behavior so that you eat less, and the calorie deficit drives the weight loss.
Who it's approved for
The FDA-approved indications for Zepbound as of April 2026:
Chronic weight management in adults with:
- Obesity (BMI of 30 or higher), or
- Overweight (BMI of 27 or higher) with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
Obstructive sleep apnea in adults with obesity (added March 2025, based on SURMOUNT-OSA).
Zepbound is meant to be used along with a reduced-calorie diet and increased physical activity, not as a standalone fix.
Pediatric use isn't approved. Tirzepatide is being studied in adolescents (trials ongoing as of 2026), but it's not yet on label for patients under 18.
The dose schedule
Zepbound comes in 6 dose strengths and is taken once per week, on the same day each week, at any time of day, with or without food.
The standard titration schedule:
| Weeks | Dose | Purpose |
|---|---|---|
| 1-4 | 2.5 mg | Starter; not for efficacy |
| 5-8 | 5 mg | First maintenance dose |
| 9-12 | 7.5 mg* | Optional intermediate step |
| 13-16 | 10 mg* | Optional intermediate step |
| 17-20 | 12.5 mg* | Optional intermediate step |
| 21+ | 15 mg | Maximum dose |
The FDA-recommended target maintenance doses are 5, 10, or 15 mg per week. The 7.5 and 12.5 mg doses are intermediate stepping stones, not endpoints. Most clinicians titrate by 2.5 mg every 4 weeks based on tolerability.
You don't have to push to 15 mg. Many patients do well at 5 or 10 mg with fewer side effects than at the top dose. The "right" dose is the lowest one that gives you the weight-loss response you want with side effects you can live with.
[Internal link to /articles/medications/zepbound-dosing-schedule/]
How much weight people lose on Zepbound
The main registration trial was SURMOUNT-1 (Jastreboff et al., NEJM 2022). It enrolled 2,539 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. None had diabetes.
Average weight loss at 72 weeks (about 17 months):
| Dose | Average weight loss |
|---|---|
| Placebo | 3.1% |
| Zepbound 5 mg | 15.0% |
| Zepbound 10 mg | 19.5% |
| Zepbound 15 mg | 20.9% |
For a person starting at 220 pounds, those numbers translate to about 33 pounds at 5 mg, 43 pounds at 10 mg, and 46 pounds at 15 mg over 17 months.
The SURMOUNT-2 trial in adults with type 2 diabetes showed a smaller (but still meaningful) effect: 12.8% loss at 10 mg and 14.7% at 15 mg over 72 weeks (Garvey et al., Lancet 2023). Diabetes blunts weight loss with all GLP-1 agents.
Other context:
- STEP 1 with semaglutide 2.4 mg: 14.9% over 68 weeks (Wilding et al., NEJM 2021).
- SURMOUNT-3 with intensive lifestyle intervention plus tirzepatide 15 mg: 26.6% loss over 88 weeks (Wadden et al., Nat Med 2023).
Real-world results tend to be a bit lower than trial averages because trial patients are highly motivated and tightly monitored. A reasonable expectation is 12-18% weight loss over 12-18 months for most patients on a maintained 10-15 mg dose with consistent diet and activity changes.
Side effects you should know about
The most common side effects from Zepbound clinical trials:
| Side effect | Frequency on 15 mg |
|---|---|
| Nausea | ~30% |
| Diarrhea | ~21% |
| Constipation | ~17% |
| Vomiting | ~13% |
| Abdominal pain | ~10% |
| Indigestion / dyspepsia | ~9% |
| Decreased appetite | Common (the intended effect) |
| Fatigue | ~6% |
| Injection site reactions | ~5% |
Most GI side effects are dose-related and concentrated in the first 4-8 weeks of each dose increase. They typically improve as your gut adapts. Slow titration, smaller meals, lower-fat foods, and adequate hydration all reduce GI complaints.
Less common but serious side effects:
- Pancreatitis. Rare. Severe, persistent abdominal pain that radiates to the back is the warning sign. Stop the drug and seek care.
- Gallbladder disease. Rapid weight loss of any kind raises gallstone risk. Right-upper-abdomen pain after fatty meals warrants evaluation.
- Diabetic retinopathy progression. A concern in patients with pre-existing retinopathy. Get a baseline eye exam.
- Thyroid C-cell tumors. Boxed warning based on rodent studies. No confirmed human cases linked to tirzepatide. Avoid in patients with personal or family history of medullary thyroid carcinoma or MEN-2.
- Hypoglycemia. Mainly when combined with insulin or sulfonylureas. Uncommon as monotherapy.
- Acute kidney injury. Rare, usually triggered by severe dehydration from vomiting or diarrhea.
- Suicidal thoughts. A theoretical class effect that the FDA has been monitoring. Current evidence does not support a causal link. Patients with a history of severe depression should be monitored.
The "Zepbound face" topic. Rapid weight loss, regardless of method, can produce facial volume loss because the face is one of the first places people lose subcutaneous fat. This isn't a Zepbound-specific side effect, but it's a frequent search query. Slower loss and adequate protein intake help.
Who shouldn't take Zepbound
Absolute contraindications:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
- Known hypersensitivity to tirzepatide or any excipient
Strong cautions:
- Pregnancy (animal data show developmental harm; not adequately studied in humans). Stop Zepbound at least 2 months before planned conception.
- Severe gastroparesis or other significant GI motility disorders
- Personal history of pancreatitis
- Severe gallbladder disease
- Active diabetic retinopathy without baseline eye exam
- BMI under 27, especially without weight-related conditions
For surgery and anesthesia: the American Society of Anesthesiologists recommends withholding GLP-1 medications for at least 1 week before elective procedures requiring sedation (ASA, 2023, updated 2024). The reason is delayed gastric emptying and aspiration risk.
For breastfeeding: insufficient data. Most prescribers avoid Zepbound during breastfeeding.
Zepbound vs Wegovy, Ozempic, Mounjaro
| Drug | Active molecule | FDA-approved use | Average weight loss in trial |
|---|---|---|---|
| Zepbound (Eli Lilly) | Tirzepatide | Chronic weight management, OSA in obesity | 15.0-20.9% over 72 weeks (SURMOUNT-1) |
| Mounjaro (Eli Lilly) | Tirzepatide | Type 2 diabetes | 11.7-15.7% in obese subgroup of diabetes trials |
| Wegovy (Novo Nordisk) | Semaglutide 2.4 mg | Chronic weight management, MACE reduction in CVD+obesity | 14.9% over 68 weeks (STEP 1) |
| Ozempic (Novo Nordisk) | Semaglutide 0.5-2.0 mg | Type 2 diabetes, MACE reduction | 6-12% in diabetes trials, less than Wegovy doses |
The two most relevant comparisons for weight-loss patients:
Zepbound vs Wegovy. Both are FDA-approved for weight loss. The SURMOUNT-1 vs STEP 1 trial comparison suggests Zepbound at 15 mg produces about 5-7 percentage points more weight loss than Wegovy at 2.4 mg. The SURMOUNT-5 head-to-head trial (Aronne et al., NEJM 2025) confirmed tirzepatide's edge: 20.2% vs 13.7% over 72 weeks.
Zepbound vs Mounjaro. Same exact molecule. Different label, different packaging. Insurance coverage differs because Mounjaro is for diabetes and Zepbound is for weight loss.
[Internal link to /articles/comparison/zepbound-vs-wegovy/]
Cost in 2026
Zepbound brand pen, retail: approximately $1,059 per month list price, before insurance.
With commercial insurance that covers it: copays range $25-200 typically, with prior authorization required by most plans.
Without insurance:
- LillyDirect self-pay vials: $349 (2.5 mg starter), $499 (5 mg), $599 (7.5 mg), $699 (10 mg), $749 (12.5 mg), $799 (15 mg) per month as of 2026 pricing.
- Eli Lilly's vial program is the cheapest legitimate cash-pay option for Zepbound.
Medicare: does not cover Zepbound for weight loss. Some plans cover it after the OSA indication for sleep-apnea use specifically. Coverage for weight loss alone remains excluded under federal Medicare rules.
Compounded tirzepatide through telehealth platforms: typically $179-349 per month. Not FDA-approved and not equivalent to brand Zepbound. We cover this option in detail below.
[Internal link to /articles/cost/zepbound-without-insurance/]
The compounded tirzepatide question
In 2024 and 2025, the FDA removed tirzepatide from its drug shortage list. This changed the rules around compounding. Under federal law, 503A and 503B compounding pharmacies can compound a drug only when it's on the FDA shortage list, with limited exceptions.
As of 2026, compounded tirzepatide is still available through some telehealth platforms under specific clinical exceptions (such as when a patient has a documented allergy to an excipient in the brand product, or when a customized dose is medically necessary). The legal landscape continues to evolve.
What you should know if you're considering compounded tirzepatide in 2026:
- It's not FDA-approved.
- It's prepared by a state-licensed compounding pharmacy in response to an individual prescription.
- It's typically drawn from a multi-dose vial with a U-100 insulin syringe.
- It's substantially cheaper than brand Zepbound.
- The legal availability depends on whether the patient meets a specific clinical exception under federal compounding rules.
A licensed clinician should walk through the trade-offs before either option starts. If brand Zepbound is affordable through insurance or LillyDirect, that's the simpler choice. Compounded options exist for patients with specific clinical needs that brand can't meet.
FAQ
What is Zepbound used for? Zepbound is FDA-approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with a weight-related condition. As of March 2025, it's also approved for obstructive sleep apnea in adults with obesity.
Is Zepbound the same as Mounjaro? Yes, the active drug (tirzepatide) is identical. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight loss and OSA. Same molecule, same doses, different label.
How fast does Zepbound work? Most patients notice reduced appetite within the first 1-2 weeks. Measurable weight loss typically appears by week 4. The 5 mg dose (week 5 onward) is the first dose with full clinical effect. Steady weight loss continues for 12-18 months on most patients before plateauing.
How much weight will I lose on Zepbound? Trial averages were 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks (Jastreboff et al., NEJM 2022). Real-world results are usually a bit lower (12-18%). Individual results vary widely based on diet, activity, baseline weight, and genetic factors.
Is Zepbound a GLP-1? Yes and more. Zepbound is a dual GIP and GLP-1 receptor agonist. It activates GLP-1 receptors (like Wegovy and Ozempic) and also GIP receptors (which Wegovy and Ozempic don't). The dual action appears to produce more weight loss than GLP-1 alone.
Is Zepbound an injection or a pill? Injection. It's delivered weekly via a single-use auto-injector pen under the skin (subcutaneously). No oral form of tirzepatide is FDA-approved as of April 2026.
Where do you inject Zepbound? The abdomen (avoiding 2 inches around the belly button), the thigh, or the upper outer arm. Rotate sites between injections. Don't inject into damaged or scarred skin.
Can I drink alcohol on Zepbound? Light drinking is generally not contraindicated, but alcohol increases nausea, dehydration, and hypoglycemia risk (especially if you're also on insulin or sulfonylureas). Many patients lose interest in alcohol on Zepbound, which is a documented effect (Klausen et al., JAMA Psychiatry 2024).
What happens if I miss a dose? If it's been less than 4 days since your scheduled dose, take it as soon as you remember. If it's been more than 4 days, skip the missed dose and take the next one on your regular weekly schedule. Don't double up.
Is Zepbound safe long-term? Long-term safety data extend to about 5 years from extended SURMOUNT trials and SURPASS diabetes trials. No new safety signals beyond the GI effects, gallbladder events, and the (so far theoretical) thyroid risk listed in the boxed warning. Obesity is chronic, and most clinicians treat Zepbound as a long-term medication.
What happens when I stop Zepbound? Most patients regain a substantial portion of lost weight after stopping. The SURMOUNT-4 trial showed patients regained about half of their lost weight within 12 months of stopping (Aronne et al., JAMA 2024). Slower regain is possible with continued lifestyle changes, but most published evidence supports indefinite continuation for weight maintenance.
How is Zepbound different from Wegovy? Different molecules. Zepbound is tirzepatide (dual GIP/GLP-1). Wegovy is semaglutide (GLP-1 only). Head-to-head, Zepbound 15 mg produced more weight loss than Wegovy 2.4 mg in the SURMOUNT-5 trial (Aronne et al., NEJM 2025).
Sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2023;29(11):2909-2918.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
- Aronne LJ, Frias JP, Friedrichsen M, et al. Tirzepatide vs semaglutide once weekly in adults with overweight or obesity (SURMOUNT-5). N Engl J Med. 2025;392(15):1387-1397.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Klausen MK, Jensen ME, Moller M, et al. Effects of semaglutide on alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2024;81(7):699-708.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. Initial approval November 2023, updated 2025.
- U.S. Food and Drug Administration. Zepbound approved for obstructive sleep apnea in adults with obesity. Press release, March 2025.
- American Society of Anesthesiologists. ASA consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. 2023, updated 2024.
- American Diabetes Association. Standards of Care in Diabetes 2026: pharmacologic approaches to glycemic treatment.
- Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective owners (Eli Lilly and Company; Novo Nordisk A/S). FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.